Clinical Trial Update: 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating 131I-apamistamab-based conditioning for hematopoietic stem cell transplantation in patients with advanced sickle cell disease and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• 131I-Apamistamab (131I-apamistamab)

Snippet

Sponsor: Columbia University | Conditions: Sickling Disorder Due to Hemoglobin S | Phase 1 | Status: RECRUITING